Business Wire

ADVA

24.3.2021 08:02:08 CET | Business Wire | Press release

Share
Vodafone Romania uses ADVA NOS in trial of DCSG

ADVA (FSE: ADV) today announced that Vodafone Romania is using its carrier-grade network operating system (NOS) in a key trial of disaggregated cell site gateway (DCSG) technology in a live nationwide network. Built with ADVA’s Ensemble Activator software running on Edgecore’s new family of DCSG devices, the open multi-vendor transport network succeeded in carrying 2G, 3G, 4G and 5G traffic while also interoperating with Vodafone’s existing infrastructure. The trial is a key step towards Vodafone validating the disaggregated model.

“We are pleased to contribute to the innovation in the field of open telecom networks, facilitating the validation of the open cell site gateway concept in a live network scenario while following our existing standard practices and processes. It was a smooth introduction, proving that the concept of open telecom networks where hardware is decoupled from software is feasible – not only in core network platforms through virtualization and in mobile radio access networks through the OpenRAN, but now also in the IP transport layer,” said Catalin Buliga, CTO, Vodafone Romania. “Mobile networks have been for years locked into a limited number of traditional telecom equipment vendors. By investing in developing open networks, where the hardware and software are decoupled, we open the gate to a wide range of suppliers for hardware, a wide range of suppliers for software, we accelerate innovation and increase our resilience.”

By using ADVA and Edgecore’s technology in a complete and fully tested DCSG offering, the trial gives Vodafone Romania insight into new mobile transport opportunities. Developed within the Telecom Infra Project’s Open Optical & Packet Transport group, the solution provides an open, agile and scalable solution able to meet today’s protocol requirements and is adaptable with future needs. Its hardware-supported SyncE and IEEE 1588 timing, with optional SFP-based GNSS backup, fulfills the most stringent synchronization accuracy requirements.

“This latest trial highlights how major mobile network operators have an alternative simple and cost-effective route to the deployment for 5G services. Our open and feature-rich Ensemble Activator NOS and Edgecore’s high-performance white boxes free network operators from closed proprietary systems. They enable them to deploy vendor-neutral disaggregated architectures using best-in-class components,” commented Eli Angel, VP, product line management, ADVA. “Today’s customers expect vendors to work side by side and build open solutions that can easily fit into complex heterogeneous environments. But while some in the industry do little more than talk about their commitment to collaboration and openness, we’re continually proving it. Now, trials like this are making the value of our approach abundantly clear.”

“As the leading provider of open network solutions to Tier 1 operators worldwide, and the leading contributor to the OCP, ONF, and TIP open communities, Edgecore understands the requirement to accelerate the innovation of disaggregated open network deployments while moving toward a more consistent and open infrastructure across mobile broadband and transport networks,” noted George Tchaparian, CEO and president, Edgecore Networks. “This successful live trial in Romania is yet another proof point that open networking is robust and deployable in the most demanding network environments.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/pages/ADVA-Optical-Networking/37630238931

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye